Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences
April 15 2021 - 6:00AM
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development
and manufacturing organization (CDMO) dedicated to solving complex
formulation and manufacturing challenges for companies developing
oral solid dose drug products, today announced the signing of
additional agreements with an existing customer, Ensysce
Biosciences, Inc. (“Ensysce”). Under these new agreements, Recro
will provide early-stage development and manufacturing services to
support two of Ensysce’s development programs. Recro and Ensysce
have already commenced the initial phase of these projects.
“We are delighted that Ensysce has elected to
expand our relationship by selecting Recro as their CDMO to support
the development of these important drug candidates. The ability to
partner with a company that is committed to applying its
proprietary technology platform to addressing the ongoing opioid
crisis in a novel way is a privilege to the entire Recro team,”
said Richard Sidwell, Ph.D., chief scientific officer of
Recro. “These latest agreements with Ensysce provide further
evidence of the momentum we continue to generate toward our dual
goals of revenue growth and customer base diversification. We are
pleased to have Ensysce on our growing list of customers.”
Lynn Kirkpatrick, Ph.D., chief executive officer
of Ensysce Biosciences, commented, “Ensysce is happy to partner
with Recro to advance the development of our clinical programs.
Recro’s experience with oral solid dosage forms, positive track
record with regulatory agencies, and high touch partnership
approach to working with customers will support our efforts to
bring novel, abuse and overdose resistant relief to patients
suffering from chronic pain.”
About RecroRecro (NASD: REPH)
is a contract development and manufacturing organization (CDMO)
with capabilities from early feasibility to commercial
manufacturing. With expertise in solving complex manufacturing
problems, Recro is a CDMO providing oral solid dosage form
development, end-to-end regulatory support, clinical and commercial
manufacturing, and packaging and logistics services to the global
pharmaceutical market.
In addition to our experience in handling DEA
controlled substances and developing and manufacturing modified
release oral solid dosage forms, Recro has the expertise to deliver
on our clients’ pharmaceutical development and manufacturing
projects, regardless of complexity level. We do all of this in our
best-in-class facilities, which total 120,000 square feet, in
Gainesville, Georgia.
For more information about Recro’s CDMO
solutions, visit recrocdmo.com.
About Ensysce
BiosciencesEnsysce Biosciences, San Diego CA, is
transforming pain management through chemistry. Its TAAP prodrug
abuse deterrent and MPAR™ overdose resistant pain platforms, with
worldwide intellectual patent protection, reduce the ability to
abuse and overdose with opioid products, a leading issue in the US
that has been intensified by the COVID pandemic and that leads to
billions in healthcare costs annually. Ensysce has recently
announced its merger with Leisure Acquisition Corp.
About Leisure Acquisition
Corp.LACQ is a blank check company formed for the purpose
of effecting a merger or other business combination with a target
company. Leisure is led by Lorne Weil and Daniel
Silvers and completed its Initial Public Offering in December
2017. Leisure is listed on the Nasdaq Capital Market (NASDAQ: LACQ,
LACQU, LACQW). Additional information can be found
at www.leisureacq.com.
Cautionary Statement Regarding Forward
Looking StatementsThis press release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These statements, among other things, relate to the
Company’s ability to manage costs and to achieve its financial
goals; to operate under increased leverage and associated lending
covenants; to pay its debt under its credit agreement and to
maintain relationships with CDMO commercial partners and develop
additional commercial partnerships. The words "anticipate",
"believe", "could", "estimate", “upcoming”, "expect", "intend",
"may", "plan", "predict", "project", "will" and similar terms and
phrases may be used to identify forward-looking statements in this
press release. Our operations involve risks and uncertainties, many
of which are outside our control, and any one of which, or a
combination of which, could materially affect our results of
operations and whether the forward-looking statements ultimately
prove to be correct. Factors that could cause the Company’s actual
outcomes to differ materially from those expressed in or underlying
these forward-looking statements include the ongoing economic and
social consequences of the COVID-19 pandemic, including any adverse
impact on the customer ordering patterns or inventory rebalancing
or disruption in raw materials or supply chain; demand for the
Company’s services, which depends in part on customers’ research
and development and the clinical plans and market success of their
products; customers' changing inventory requirements and
manufacturing plans; customers and prospective customers decisions
to move forward with the Company’s manufacturing services; the
average profitability, or mix, of the products the Company
manufactures; the Company’s ability to enhance existing or
introduce new services in a timely manner; fluctuations in the
costs, availability, and suitability of the components of the
products the Company manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials, or
the Company’s customers facing increasing or new competition. These
forward-looking statements should be considered together with the
risks and uncertainties that may affect our business and future
results presented herein along with those risks and uncertainties
discussed in our filings with the Securities and Exchange
Commission at www.sec.gov. These forward-looking statements are
based on information currently available to us, and we assume no
obligation to update any forward-looking statements except as
required by applicable law.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Recro
(484) 395-2436
ryan.lake@recroCDMO.com
Leisure Acquisition (NASDAQ:LACQW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Leisure Acquisition (NASDAQ:LACQW)
Historical Stock Chart
From Oct 2023 to Oct 2024